Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Dinoprost tromethamine
Drug ID BADD_D00683
Description The tromethamine (THAM) salt of the naturally occurring prostaglandin F2 alpha, dinoprost tromethamine occurs as a white to off-white, very hygroscopic, crystalline powder. Dinoprost tromethamine may also be known as dinoprost trometamol, PGF2 alpha THAM, or prostaglandin F2 alpha tromethamine.
Indications and Usage Used for aborting second-trimester pregnancy (between the twelfth to eighteenth week of gestation) and in incomplete abortion or for therapeutic abortion in cases of intrauterine fetal death and congenital abnormalities incompatible with life. Also used at low-doses for medically indicated induction of labor at term. Also injected intra-arterially for use as a vasodilator to assist in angiography.
Marketing Status approved; vet_approved
ATC Code Not Available
DrugBank ID DB01160
KEGG ID D01352
MeSH ID C010714
PubChem ID 5282415
TTD Drug ID D04RGA
NDC Product Code 69870-088; 0009-5031
UNII CT6BBQ5A68
Synonyms dinoprost tromethamine | PGF2alpha tromethamine | prostaglandin F2alpha tromethamine | Lutalyse | Minprostin F2 Alpha | Prostin F2 | Prostin F2 Alpha
Chemical Information
Molecular Formula C24H45NO8
CAS Registry Number 38562-01-5
SMILES CCCCCC(C=CC1C(CC(C1CC=CCCCC(=O)O)O)O)O.C(C(CO)(CO)N)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Agitation19.06.02.001; 17.02.05.012--
Asthenia08.01.01.001--Not Available
Atrioventricular block second degree02.03.01.005--
Back pain15.03.04.005--
Body temperature increased13.15.01.001--Not Available
Bradycardia02.03.02.002--Not Available
Breast engorgement21.05.05.002; 18.08.02.001--Not Available
Bronchospasm22.03.01.004; 10.01.03.012--
Burning sensation17.02.06.001; 08.01.09.029--Not Available
Cardiac arrest02.03.04.001--
Cardiac failure congestive02.05.01.002--Not Available
Chest pain22.12.02.003; 08.01.08.002; 02.02.02.011--Not Available
Chills08.01.09.001; 15.05.03.016--
Cough22.02.03.001--
Cyanosis23.06.04.005; 02.11.04.004; 24.03.01.007; 22.02.02.007--
Dehydration14.05.05.001--
Dermatitis23.03.04.002--Not Available
Diabetes mellitus14.06.01.001; 05.06.01.001--Not Available
Diarrhoea07.02.01.001--
Diplopia17.17.01.005; 06.02.06.002--Not Available
Discomfort08.01.08.003--Not Available
Dizziness17.02.05.003; 02.11.04.006; 24.06.02.007--
Dyspnoea02.11.05.003; 22.02.01.004--
Dysuria20.02.02.002--
Epistaxis24.07.01.005; 22.04.03.001--
Feeling abnormal08.01.09.014--Not Available
Haematuria21.10.01.018; 24.07.01.047; 20.02.01.006--
Headache17.14.01.001--
Hiccups22.12.01.001; 07.01.06.009--
Hyperhidrosis23.02.03.004; 08.01.03.028--
The 1th Page    1 2 3    Next   Last    Total 3 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene